Premarket Action Heats Up For This Micro Cap

Sponsored:

Wednesday, January 17, 2024

A Maryland-based healthcare company is causing quite the stir so far during Wednesday’s premarket after the company announced early results from its collaboration with the Lieber Institute for Brain Development (LIBD) that could revolutionize the understanding and treatment of psychiatric disorders.

According to the release, “the early findings from this global strategic partnership have successfully stratified brain expression data, offering what may turn out to be unprecedented insights into psychiatric conditions.”

Traders were over the moon about the news as they quickly bought up shares of Bullfrog AI Holdings Inc. (Nasdaq:BFRG). Shares are currently bid up at $3.22/share (+21.97% implied open for sellers) at the time of writing. It should be an exciting session for this micro cap!

Bullfrog AI Holdings, Inc. is a digital biopharmaceutical company. The Company is focused on advanced artificial intelligence/machine learning (AI/ML)-driven analysis of complex data sets in medicine and healthcare. The Company’s platform technology, bfLEAP, is an analytical AI/ML platform that is a potentially disruptive tool for the analysis of pre-clinical and/or clinical data sets, such as the robust pre-clinical and clinical trial data sets being generated in translational R&D and clinical trial settings. The platform can capture the genetic and physical characteristics of patients in an unbiased manner and contextualize them against other disparate data sources from patients. The Company’s therapeutic pipeline includes siRNA and Mebendazole. Its siRNA targets Beta2-spectrin in the treatment of human diseases such as hepatocellular carcinoma (HCC), obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis. Mebendazole is focused on targeting Glioblastoma.

Sponsored: